Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 18321849 
Song P, et al. (2008) Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation increases LKB1 nucleus export and apoptosis in endothelial cells. J Biol Chem 283, 12446-55 18321849
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S473-p - Akt1 (human)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer, cervical cancer, cervical adenocarcinoma
 Relevant cell lines - cell types - tissues:  HeLa S3 (cervical), HUVEC (endothelial), MDA-MB468 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ONOO(-) decrease
KT5823 ONOO(-) no effect upon treatment-induced decrease
H-89 ONOO(-) no effect upon treatment-induced decrease
bisindolylmaleimide ONOO(-) inhibit treatment-induced decrease
PKC-zeta inhibitor ONOO(-) inhibit treatment-induced decrease
ONOO(-) LKB1 (human) inhibit treatment-induced decrease deficient cells or dominant negative expression
ONOO(-) PTEN (human) inhibit treatment-induced decrease deficient cells
H2O2 increase
spermine increase
Sin-1 decrease

S428-p - LKB1 (human)
Orthologous residues
LKB1 (human): S428‑p, LKB1 iso2 (human): , LKB1 (mouse): S431‑p, LKB1 (rat): S431‑p, LKB1 (pig): S339‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer, cervical cancer, cervical adenocarcinoma
 Relevant cell lines - cell types - tissues:  HeLa S3 (cervical), HUVEC (endothelial), MDA-MB468 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE PKCZ (human)
KINASE LKB1 (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ONOO(-) increase
siRNA ONOO(-) PKCZ (human) inhibit treatment-induced increase
PKC-zeta inhibitor ONOO(-) inhibit treatment-induced increase
Sin-1 increase
Downstream Regulation
 Effect of modification (function):  intracellular localization, phosphorylation

T410-p - PKCZ (human)
Orthologous residues
PKCZ (human): T410‑p, PKCZ (mouse): T410‑p, PKCZ (rat): T410‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer, cervical cancer, cervical adenocarcinoma
 Relevant cell lines - cell types - tissues:  HeLa S3 (cervical), HUVEC (endothelial), MDA-MB468 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ONOO(-) increase
PKC-zeta inhibitor ONOO(-) inhibit treatment-induced increase
Sin-1 increase

S380-p - PTEN (human)
Orthologous residues
PTEN (human): S380‑p, PTEN (mouse): S380‑p, PTEN (rat): S380‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer, cervical cancer, cervical adenocarcinoma
 Relevant cell lines - cell types - tissues:  HeLa S3 (cervical), HUVEC (endothelial), MDA-MB468 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE PKCZ (human)
KINASE LKB1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE LKB1 (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, inhibition of upstream enzyme, pharmacological activator of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ONOO(-) increase
siRNA ONOO(-) PKCZ (human) inhibit treatment-induced increase
PKC-zeta inhibitor ONOO(-) inhibit treatment-induced increase
Sin-1 increase

T382-p - PTEN (human)
Orthologous residues
PTEN (human): T382‑p, PTEN (mouse): T382‑p, PTEN (rat): T382‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer, cervical cancer, cervical adenocarcinoma
 Relevant cell lines - cell types - tissues:  HeLa S3 (cervical), HUVEC (endothelial), MDA-MB468 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE PKCZ (human)
KINASE LKB1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE LKB1 (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, inhibition of upstream enzyme, pharmacological activator of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ONOO(-) increase
siRNA ONOO(-) PKCZ (human) inhibit treatment-induced increase
PKC-zeta inhibitor ONOO(-) inhibit treatment-induced increase
Sin-1 increase

T383-p - PTEN (human)
Orthologous residues
PTEN (human): T383‑p, PTEN (mouse): T383‑p, PTEN (rat): T383‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer, cervical cancer, cervical adenocarcinoma
 Relevant cell lines - cell types - tissues:  HeLa S3 (cervical), HUVEC (endothelial), MDA-MB468 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE LKB1 (human)
KINASE PKCZ (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE LKB1 (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, inhibition of upstream enzyme, pharmacological activator of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ONOO(-) increase
siRNA ONOO(-) PKCZ (human) inhibit treatment-induced increase
PKC-zeta inhibitor ONOO(-) inhibit treatment-induced increase
Sin-1 increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.